Bob Repella - CSL President
| CSLLY Stock | USD 90.71 1.54 1.73% |
President
Mr. Bob Repella is Executive Vice President Global Commercial Operations of CSL Ltd. He was appointed as Executive Vice President, Global Commercial Operations in July 2014 with responsibility for a variety of global functions including sales, marketing, commercial development, medical affairs and public policy. Prior to joining CSL, he held senior management roles at a number of pharmaceutical companies including Cephalon and Wyeth. Bob has over 30 years of commercial experience including biotech and specialty markets. since 2014.
| Age | 57 |
| Tenure | 10 years |
| Phone | 61 3 9389 1911 |
| Web | https://www.csl.com.au |
CSL Management Efficiency
The company has return on total asset (ROA) of 0.0613 % which means that it generated a profit of $0.0613 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1338 %, meaning that it generated $0.1338 on every $100 dollars invested by stockholders. CSL's management efficiency ratios could be used to measure how well CSL manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0613 |
CSL Leadership Team
Elected by the shareholders, the CSL's board of directors comprises two types of representatives: CSL inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CSL. The board's role is to monitor CSL's management team and ensure that shareholders' interests are well served. CSL's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CSL's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul McKenzie, Chief Officer | ||
| Alan Wills, Senior Vice President of Strategy and Business Development | ||
| BS BS, Exec Counsel | ||
| Val Romberg, Executive Vice President of Manufacturing and Planning | ||
| Edward Bailey, Company Secretary | ||
| Brian McNamee, Non-Executive Independent Director | ||
| Bill Campbell, Executive Vice President Chief Commercial Officer | ||
| Wilfried Freudenberg, Department Production | ||
| Bob Repella, Executive Vice President - Global Commercial Operations | ||
| Abbas Hussain, Director | ||
| Bernard Ronchi, Senior Manager, Investor Relations | ||
| Laurie Cowan, Sr. VP of HR | ||
| MS BA, Ex Officer | ||
| Greg Boss, Group General Counsel, Executive Vice President - Legal | ||
| John Akehurst, Independent Non-Executive Director | ||
| Karen Etchberger, Executive VP of Quality and Bus. Services | ||
| Jemimah Brennan, Head Pacific | ||
| Mark Dehring, Head of Investor Relations | ||
| Fiona Mead, Company Secretary and Head of Group Governance | ||
| Andrew Cuthbertson, Chief Scientific Officer, R&D Director | ||
| Megan Clark, Director | ||
| Paul Perreault, CEO, Managing Director, Executive Director | ||
| Robert Cuthbertson, Chief Scientific Officer, R&D Director, Director | ||
| David Anstice, Independent Non-Executive Director | ||
| Shah Hussain, Director | ||
| Paul BA, CEO MD | ||
| Bruce Brook, Independent Non-Executive Director | ||
| Christine OReilly, Independent Non-Executive Director | ||
| Mary Sontrop, Executive Vice President - Manufacturing and Planning | ||
| BCom BComm, Chief Officer | ||
| Gordon Naylor, CFO | ||
| David Lamont, CFO | ||
| Laurie Reed, Senior Vice President - Human Resources | ||
| Tadataka Yamada, Director | ||
| Elizabeth Walker, Chief Human Resource Officer, Executive Vice President | ||
| Christina Hickie, Sr Communications | ||
| Marie McDonald, Independent Non-Executive Director | ||
| John Shine, Independent Non-Executive Chairman of the Board | ||
| Maurice Renshaw, Independent Non-Executive Director | ||
| Robert Repella, Executive Vice President - Global Commercial Operations | ||
| John Levy, Company Secretary |
CSL Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CSL a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | |||
| Return On Asset | 0.0613 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 96.65 B | |||
| Shares Outstanding | 964.43 M | |||
| Shares Owned By Institutions | 0.07 % | |||
| Price To Earning | 34.45 X | |||
| Price To Book | 6.77 X | |||
| Price To Sales | 9.04 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CSL in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CSL's short interest history, or implied volatility extrapolated from CSL options trading.
Pair Trading with CSL
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CSL position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CSL will appreciate offsetting losses from the drop in the long position's value.Moving together with CSL Pink Sheet
| 0.88 | CMXHF | CSL Limited | PairCorr |
| 0.65 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against CSL Pink Sheet
| 0.59 | SGEN | Seagen Inc Earnings Call This Week | PairCorr |
| 0.59 | WMT | Walmart Financial Report 16th of May 2024 | PairCorr |
| 0.5 | TSM | Taiwan Semiconductor Financial Report 18th of July 2024 | PairCorr |
| 0.49 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.48 | NONOF | Novo Nordisk AS | PairCorr |
The ability to find closely correlated positions to CSL could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CSL when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CSL - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CSL to buy it.
The correlation of CSL is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CSL moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CSL moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CSL can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CSL. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for CSL Pink Sheet analysis
When running CSL's price analysis, check to measure CSL's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CSL is operating at the current time. Most of CSL's value examination focuses on studying past and present price action to predict the probability of CSL's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CSL's price. Additionally, you may evaluate how the addition of CSL to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |